MacroGenics Q1 2026 Earnings Report

MacroGenics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.56
• Beat/Miss: N/A
• One Year Ago EPS: N/A

MacroGenics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $16.29 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

MacroGenics Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Friday, May 15, 2026
• Conference Call Time: 4:00PM ET

MacroGenics (NASDAQ:MGNX) is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies. The ADAPTIR platform enables the design of multi-specific antibodies with modular binding domains, allowing precise activation of immune cells. The Trident format supports the simultaneous targeting of three molecular entities, potentially improving selectivity and efficacy. These platforms underpin a diversified pipeline that spans oncology indications as well as immuno-oncology combinations and autoimmune disease targets.

Based in Rockville, Maryland, MacroGenics conducts its research and early development in the United States and collaborates with clinical trial centers across North America, Europe and Asia. Strategic partnerships with companies such as Merck, Servier and Kyowa Kirin have supported late-stage development, regulatory filings and potential commercialization in territories outside the United States. These alliances enhance the company’s ability to bring innovative therapies to a broader patient population.

Leadership at MacroGenics is headed by President and Chief Executive Officer Scott Koenig, who draws on extensive experience in oncology drug development to guide strategic and operational initiatives. The company’s governance is further strengthened by a scientific advisory board and an experienced management team, all of whom are committed to advancing novel antibody therapeutics through rigorous research and clinical evaluation.